It wasn’t all that long ago that Lundbeck had fallen on hard times. But thanks to some new launches—and some new leadership to oversee them—the company is poised to post its best-ever financial year. More: New launches Rexulti, Trintellix steer
read moreIt takes some mighty big forces to shift the enormous drugmakers that, like boulders in a stream, help define the course of the pharma industry. But shift they did over the last decade, and there’s a story behind every changing
read morePerrigo Thursday delivered something that’s gotten pretty scarce as of late: a generics beat. The company’s branded generics unit delivered $240 million in second-quarter revenue, passing the Street’s $224 million expectations on the back of increased sales of higher-margin products,
read moreExperimental treatment to target advanced lung tumours More: Cancer Research UK and Biotecnol to trial new immunotherapy Source: News
read moreSmall companies could introduce a “golden age” of next-gen therapies like CAR-T, combination therapies, and immunotherapy More: Biotech to drive biggest cancer advancements in decades – report Source: News
read moreM&A, investment and digital health strong for the first half of 2017 More: Positive outlook for biotech M&A and funding, says report Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals